Integra Lifesciences Holdings (IART) Cash & Current Investments (2009 - 2026)

Integra Lifesciences Holdings has reported Cash & Current Investments for 18 years, with the latest figure at $274.1 million in Q2 2026.

• Quarterly Cash & Current Investments rose 8.08% year-over-year to $274.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $274.1 million (up 8.08% YoY) and the FY2025 annual result came in at $263.7 million, down 3.59% from the prior year.
• Cash & Current Investments climbed to $274.1 million in Q2 2026 per IART's latest filing, from $265.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $663.1 million in Q1 2024 and troughed at $253.6 million in Q2 2025.
• A 5-year average of $340.6 million and a median of $287.3 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments surged 115.74% in 2024, then sank 58.78% in 2025.
• Over 5 years, Cash & Current Investments stood at $456.7 million in 2022, then sank by 32.31% to $309.1 million in 2023, then decreased by 11.49% to $273.6 million in 2024, then slipped by 3.59% to $263.7 million in 2025, then grew by 3.93% to $274.1 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $274.1 million, $265.5 million, and $263.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.